1

October 7, 2019 Wyndham H. Wilson

CURRICULUM VITAE Name: Wyndham Hopkins Wilson Citizenship: United States Place of Birth: San Francisco, California Home Address: 84 Princeton Road Menlo Park, CA, 94025 Work Address: Building 10, Room 4N-115

National Cancer Institute 9000 Rockville Pike Bethesda, Maryland 20892

(O) 301-435-2415 (M) 301-312-5484

Current Position: Chief, Lymphoma Therapeutics Section Deputy Chief, Lymphoid Malignancies Branch

Center for Cancer Research National Cancer Institute

Education 1970-1974 B.A. (Human Biology)

Stanford University, Stanford, CA 1974-1975 M.S. (Biology)

Stanford University, Stanford, CA 1975-1981 Ph.D. (Neurobiology)

Stanford University, Stanford, CA

M.D. (Stanford School of Medicine) Stanford University, Stanford, CA

2

Positions 1976-1977 Teaching Assistant, Department of Neurobiology, Stanford University, Stanford, CA 1978 Acting Assistant Instructor, Department of Neurobiology,

Stanford University, Stanford, CA 1979-1980 Teaching Assistant, Department of Neurobiology, Stanford

University, Stanford, CA 1981-1982 Internship, Department of Medicine,

Stanford University, Stanford, CA 1982-1984 Junior and Senior Resident, Department of Medicine, Stanford

University, Stanford, CA 1984-1987 Medical Staff Fellow, Medicine Branch, National Cancer In-

stitute, NIH, Bethesda, MD 1985-1994 Emergency Department Physician, City Hospital, Martinsburg,

West Virginia (Part-time). 1987-1988 Medical Staff Fellow, Pediatric Branch, Infectious Disease

Section, National Cancer Institute, NIH, Bethesda, MD 1988-1995 Special Assistant to the Director, Division of Cancer Treatment,

National Cancer Institute, NIH, Bethesda, MD 1995-2002 Senior Investigator, Medicine Branch, Division of Clinical

Sciences, National Cancer Institute, NIH, Bethesda, MD 1997-2008 Chief, Lymphoma Clinic, Medicine Branch, Division of Clinical

Sciences, National Cancer Institute, NIH, Bethesda, MD 1997-1998 Oncology Fellowship Coordinator, Medicine Branch, Division of

Clinical Sciences, National Cancer Institute, NIH, Bethesda, MD

1998-1999 Chief, Clinical Core, Metabolism Branch, Division of Clinical

Sciences, National Cancer Institute, NIH, Bethesda, MD 2002-2005 Senior Investigator, Chief, Lymphoma Section, Experimental

Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, MD.

3

2005-Present Senior Investigator, Chief, Lymphoma Therapeutics Section, Lymphoid Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

2013-Present Deputy Branch Chief, Lymphoid Malignancy Branch, Center for

Cancer Research, National Cancer Institute, Bethesda, MD

Licensed to Practice Medicine

West Virginia License # 14230

Certification

1982 Diplomat, National Board of Medical Examiners 1985 Diplomat, American Board of Internal Medicine 1987 Diplomat, Subspecialty of Oncology, American Board of

Internal Medicine

Society Membership 1996-Present American Society of Hematology

Committees at NIH

1988-1989 Chairman, Fluoro-dideoxyinosine and Fluoro-dideoxycytidine Licensing Committee, DCT, NCI

1988-1995 Chairman, Animal Care and Use Committee, DCT, NCI 1992-1993 Member, Natural Products Repository Review Committee 1992-1995 Member, Institutional Review Board, NCI 1995-2008 Member, Protocol Review and Monitoring Committee, DCS, NCI 1995-2002 Chairman, Institutional Review Board, NCI 1999-2001 Member, Promotions and Tenure Review Committee, DCS, NCI

4

2001-2007 Chairman, Promotions and Tenure Review Committee for Clinical Staff, CCR, NCI

Academic Honors

1974 B.A. with Honors in Human Biology 1976-1981 Medical Scientist Training Program Grant Award 1994 Merit Award, National Institutes of Health 1997 Teacher of the Year Award, Medicine Branch and Division of

Clinical Sciences, National Cancer Institute 1998 Director’s Award, National Institutes of Health 2000 Director’s Award, Division of Clinical Sciences, NCI 2010 Director Award, National Institutes of Health 2010 Director Award, National Caner Institute

Editorial Boards 1999-2011 Clinical Lymphoma 2000-2003 Journal of Clinical Oncology 2012-Present 2002-Present The Oncologist 2006-2011 Leukemia and Lymphoma, Associate Editor 2007-Present Blood 2008-Present Advances in Hematology 2013-Present Biomed Central Hematology 2014-Present Associate Editor, Haematologica

5

Extramural Activities 2000-Present Member, CALGB/Alliance Cooperative Group 2000-2005 Executive Director, Progress Review Group for Lymphoma,

Leukemia and Multiple Myeloma 2001 Member, Planning Committee, American Society of

Hematology Meeting, 2001 2002-Present Scientific Advisory Board, International Working Group on non-

Hodgkin’s Lymphoma (IwNHL) 2005-2006 Committee on Neoplasia, American Society of Hematology 2006-Present Committee on Lymphoid Neoplasia, American Society of

Hematology 2008-2009 Vice-Chair ASH Scientific Committee on Lymphoid Neoplasia 2009-2010 Chair ASH Scientific Committee on Lymphoid Neoplasia 2008-2012 Member, Oncologic Drug Advisory Committee (ODAC), FDA 2009-Present Scientific Advisory Board, Lymphoma Research Foundation 2009-Present Member, Lymphoma Steering Committee, Cooperative

Groups, Cancer Therapy Evaluation Program, NCI, NHI 2010-2012 Chair, Oncologic Drug Advisory Committee (ODAC), FDA

Patents and Licenses NIH Ref. E-175-1992/0-US-09; US Patent #5,496,846 “Taxol treatment of breast cancer” United States Patent RE40839 Taxol treatment of cancer NIH Ref. E-175-1992/0-US-08; International patent application # PCT/US1993/008983 “USE OF TAXOL FOR TREATING LYMPHOMAS AND BREAST CANCER” This application became an issued foreign patent throughout Europe in 2003. NIH Ref. E-065-2002/0-US-03; US application # 10/514,910 (currently pending)

6

“ELISA assay of serum soluble CD22 to assess tumor burden/relapse in subjects with leukemia & lymphoma” NIH Ref. E-091-2002/0-US-02; US Patent 7,329,502 “ZAP-70 Protein Expression as a Marker for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)” NIH Ref. E-091-2002/0-US-04; US application # 11,955,322 (currently pending divisional related to US patent #7,329,502) “ZAP-70 Protein Expression as a Marker for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)” NIH Ref. E-108-2004/1-US-01; US application #11/493,387 (currently pending) “Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas” NIH Ref. E-108-2004/0-US-01; US application # 10/934,930 (currently pending) “Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas” NIH Ref. E-108-2004/1-PCT-02; international application PCT/US2007/016843 (currently pending) “Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas”

7

Bibliography

1. Wilson WH and Heller HC: Elevated blood glucose levels and satiety in the rat.

Physiol Behav 15:137-143, 1975. 2. Burton LE, Wilson WH and Shooter EM: Nerve Growth Factor in mouse saliva;

Rapid isolation procedures for and characterization of 7 S Nerve Growth Factor. J Biol Chem 253:7807-7812, 1978.

3. Wilson WH and Shooter EM: Structural modification of the NH2-terminus of Nerve

Growth Factor; Purification and characterization of Beta-Nerve Growth Factor endopeptidase. J Biol Chem 254:6002-6009, 1979.

4. Bothwell MA, Wilson WH and Shooter EM: The relationship between glandular

kallikrein and growth factor-processing proteases of mouse submaxillary gland. J Biol Chem 254:7287-7294, 1979.

5. Jacobs MB and Wilson W: Iron deficiency anemia in a vegetarian runner. JAMA

252(4):481-482, 1984. 6. Lane CH, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, Leitman

SF, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with Zidovudine in human immunodeficiency virus infection. Ann Intern Med 113:512-519, 1990.

7. Wilson WH, Magrath I: Principles of chemotherapy. In The Non-Hodgkin's Lym-

phomas. I. Magrath, editor, Edward Arnold, publisher, London, 1990. 8. Longo DL, Wilson WH: Follicular lymphomas. In The Non-Hodgkin's Lymphomas. I.

Magrath, editor, Edward Arnold, publisher, London, 1990. 9. Barriga F, Magrath I, Wilson WH: Complications in the management of non-

Hodgkin's lymphomas. In The Non-Hodgkin's Lymphomas. I. Magrath, editor, Edward Arnold, publisher, London, 1990.

10. Magrath I, Wilson WH, Horgath M, Neumann R, Barriga F: Clinical features and

staging. In The Non-Hodgkin's Lymphomas. I. Magrath, editor, Edward Arnold, publisher, London, 1990.

11. Rothenberg M, Wilson W, Chabner BA: Complications of drug therapy for cancer:

General review. In The Complications of Cancer Management. Plowman, P.N., McElwain, T.J., and Meadows A.T., editors, Butterworth-Heinemann, publishers, U.K., 1991.

8

12. Chabner BA, Wilson WH: Reversal of multidrug resistance. [Editorial] J Clin Oncol 9:4-6, 1991.

13. Burt RK, Sharfman WH, Karp BI and Wilson WH: Mental neuropathy, a harbinger of

tumor progression or relapse. Cancer 70:877-881, 1992. 14. Urba WJ, Wilson WH, Duffey PL, Wittes R, Chabner BA and Longo DL: Recent NCI

lymphoma trials of etoposide-containing combination chemotherapy. Semin in Oncol 19:26-32, 1992.

15. Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B,

Steinberg SM, Longo DL, Wittes RE: Phase I-II Study of high-dose ifosfamide, carboplatin and etoposide (ICE) with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10:1712-1722, 1992.

16. Bergan R and Wilson WH: Pulmonary toxicity of cancer therapy. Intern Med 13:56-

65, 1992. 17. Quezado ZMN, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene

FP: High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 118:31-36, 1993.

18. Wilson WH: High-dose chemotherapy and autologous transplantation with

peripheral blood stem cells by Vose J, Armitage J, Kessinger A. [Commentary] Oncology 7:33-34, 1993.

19. Goldspiel BR, Kohler DR, Koustenis AG, Wilson WH, Tolcher AW, O’Shaughnessy

JA, Wittes RE, Chabner BA: Paclitaxel administration using portable infusion pumps. [Letter] J Clin Oncol 11:2287-2288, 1993.

20. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe

ES, Herdt J, Cheson BD, Chabner BA. EPOCH Chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993.

21. O'Shaughnessy JA, Cowan KH, Wilson W, Bryant G, Goldspiel B, Gress R,

Nienhuis AW, Dunbar C, Sorrentino B, Stewart FM, Moen R, Fox M, Leitman S: Clinical Protocol-Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. Human Gene Therapy 4:331-354, 1993.

22. Walsh TJ, Renshaw G, Andrews J, Kwon-Chung J, Cunnion RC, Pass HI,

Taubengerger J, Wilson W and Pizzo PA: Invasive Zygomycosis due to Conidiobolus incongruus. Clin Infect Dis 19:423-430, 1994.

9

23. Wilson WH: The role of GM-CSF and G-CSF in stem cell transplantation by Nemunaitis J. [Commentary] Oncology 8:17-18, 1994.

24. Chabner BA, Bates SE, Fojo AT, Spolyar M and Wilson WH: Drug resistance in

adult lymphomas. Semin in Oncol 31:70-87, 1994.

25. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox M, Leitman S, Gottesman M, Pastan I, Denicoff A, Noone M, Gress R: Clinical Protocol-Retroviral mediated transfer of the human multidrug resistance gene (mdr-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Human Gene Therapy 5:891-911, 1994.

26. Shilyansky J, Wilson W, Temeck BK and Pass HI: Pulmonary artery-bronchial fistula

during lymphoma treatment. [Letter] J Thoracic and Cardiovascular Surgery, 108:790-791, 1994.

27. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM,

Goldspiel BR, Herdt J, O’Shaughnessy J, Balis FM, Chabner BA: Paclitaxel in doxorubicin or mitoxantrone refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994.

28. Humphrey RW, Wilson WH: Treatment of non-Hodgkin's lymphoma by Armitage JO.

[Commentary] Abst Clin Care Guidelines 6:4-5, 1994. 29. Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg

SM, Goldspiel BR, Cheson BD, Wittes RE: A phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13:381-386, 1995.

30. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstein B, Lee JS, Stetler-

Stevenson MA, Jaffe E, Solomon D, Wilson WH, Chabner BA, Fojo A and Bates SE: Expression of mdr-1 in refractory lymphoma: Quantitation by PCR and validation of the assay. Blood 86:1515-1524, 1995.

31. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA,

Steinberg SM, Kohler DR, Wittes RE: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 13:1985-1994, 1995.

32. Wilson WH, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM,

Herdt J, Chabner BA: A controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13:1995-2004, 1995.

10

33. Saville MW, Jietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey R, Feigal E, Steinberg SM, Broder S and Yarchoan R: Treatment of HIV-associated Kaposi’s Sarcoma with paclitaxel. Lancet 346:26-28, 1995.

34. Chabner BA, Wilson WH: Pharmacology and toxicity of antineoplastic drugs. In

Williams Hematology, Beutler E., Lichtman M.A., Coller B.S., and Kipps T.J., editors, McGraw-Hill, Inc publishers USA, 1995.

35. Dunbar CE, Cottler-Fox M, O’Shaughnessy JA, Doren S, Carter C, Berenson R,

Brown S, Moen RC, Greenblatt J, Stewart FM, Leitman SF, Wilson WH, Cowan K, Young NS and Nienhuis AW: Retrovirally-marked CD-34 enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85:3048-3957, 1995.

36. Cheson BD, Wilson WH: Paclitaxel in the treatment of hematological malignancies.

In Paclitaxel in Cancer Treatment. McGurie, W.P. and Rowinsky, E.K., Editors, Marcel Dekkar Inc, Publisher, New York, 1995.

37. Wilson WH: Drug resistance in non-Hodgkin’s lymphomas. Lymphoma Biology and Research 1:4-5, 1995. 38. Wilson WH, Bates SE, Fojo A, Chabner BA: Modulation of multidrug resistance by

dexverapamil in EPOCH-refractory lymphomas. J Can Res Clin Oncol 121 (Suppl 3):25-29, 1995.

38. Wilson WH, Kingma DW, Wittes RE, Greiner TC and Jaffe ES: Association of

Lymphomatoid granulomatosis with Epstein-Barr Viral infection of B Lymphocytes and response to alfa-interferon. Blood 87:4531-4537, 1996.

39. Burt RK, Wilson WH: Conditioning regimens. In House Officers Manual of Bone

Marrow Transplantation. Barrett AJ, Blume KG, et al editors, R.G. Landes Company, publisher, 1996.

40. Prussick R, Horn TD, Wilson WH and Turner MC: A cutaneous eruption associated

with ifosfamide, carboplatin and etoposide chemotherapy after recombinant interleukin-1a pretreatment. J Amer Acad Derm, 35:705-709, 1996.

41. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C,

Monks A, Kang YK, Chabner B: Clinical reversal of multidrug resistance. Oncologist, 1:269-275, 1996.

42. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld

M: Relationship of p53, bcl-2 and MIB-1 proliferative antigen to clinical drug resistance in non-Hodgkin’s lymphoma. Blood, 89:601-609, 1997.

11

43. Georgiadis MS, Schuler BS, Brown JE, Kieffer LV, Steinberg SM, Wilson WH, Takimoto CH, Kelley MJ, Johnson BE: Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer. J Clin Oncol 15:735-743, 1997.

44. Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson WH, Fojo AT, Bates

SE: Expression of the multidrug resistance-associated protein gene in refractory lymphoma: Quantitation by a validated polymerase chain reaction assay. Blood 89:3795-3800, 1997.

45. Wilson WH, Chabner BA: Principles of therapy. In The Lymphomas. G. Canellos,

T.A. Lister, J.L. Sklar, editors, W.B. Saunders, Publisher, 1997. 46. Segal BH, Engler HD, Little R, Wilson WH, Freifeld AG, Chanock SJ: Early forscarnt

failure in herpes simplex virus infection in a patient with AIDS. AIDS 11:552-553, 1997.

47. Molldrem J, Wilson WH: Infusional chemotherapy for non-Hodgkin’s lymphoma.

Cancer Invest 15:465-474, 1997. 48. Wilson WH: The role of dose intensity in the treatment of HIV-associated

lymphomas. N Engl J Med [letter] 337:1172-1173, 1997. 49. Wilson WH: Principles of chemotherapy. In The Non-Hodgkin's Lymphomas.

(Second Edition), I. Magrath, editor, Edward Arnold, Publisher, London, 1997. 50. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH,

Longo DL, Tosato G: The role of Mig, the monokine induced by interferon-g, and IP-10, the interferon-g inducible protein 10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 15:4099-4105, 1997.

51. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Wilson WH, Wittes RE, Jaffe

ES, Hubbard SM, DeVita Jr. VT: Alternating MOPP and ABVD plus mantle field radiation therapy in patients with massive mediastinal Hodgkin’s disease. J Clin Oncol 15:3338-3346, 1997.

52. Sandor V, Wilson W, Fojo A, Bates SE: The role of MDR-1 in refractory lymphoma.

Leuk Lymph 28:23-31, 1997. 53. Jaffe ES, Wilson WH: Lymphomatoid granulomatosis: Pathogenesis, pathology and

clinical implications. Cancer Surv 30:233-248, 1997. 54. Wilson WH: Pharmacokinetics of chemotherapy agents by continuous infusion: The

Paclitaxel Module. In Infusion Chemotherapy-Radiation Interaction: Its Biology and Significance for Organ Salvage and Prevention of Second Primary Neoplasms. C.

12

Julian Rosenthal and Marvin Rotman, editors, Elsevier, Publisher, Amsterdam, 1998.

55. Mickley LA, Lee JS, Weng Z, Alvarez M, Wilson W, Bates SE, Fojo AT: Genetic

polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91:1749-1756, 1998.

56. Little R, Wittes RE, Longo DL, Wilson WH: Vinblastine in recurrent Hodgkin’s

disease following autologous stem cell transplant. J Clin Oncol 16:584-588, 1998. 57. Weng DE, Wilson WH, Little RL, Walsh TJ: Successful medical management of

isolated renal Zygomycosis: A case report and literature review. Clin Infect Dis 26:601-605, 1998.

58. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill K, Feuerstein I, Figg WD, Lush R,

Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Steinberg SM, Broder S, Yarchoan R: Phase II trial with dose tiration of paclitaxel for the therapy of Human Immunodeficiency Virus-associated Kaposi’s sarcoma. J Clin Oncol 16:1112-1121, 1998.

59. Adde M, Shad A, Venzon D, Arndt C, Gootenberg J, Neely J, Nieder M, Owen W,

Seibel N, Wilson W, Horak ID, Magrath I: Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncology 25 (Suppl 4):33-39; discussion 45-48, 1998.

60. Wilson WH, Little R, Pearson D, Jaffe E, Steinberg S, Cheson BD, Humphrey R,

Kohler D, Elwood P. A phase II and dose escalation � G-CSF study of 9-aminocamptothecin in relapsed and refractory lymphomas. J Clin Oncol 16:2345-2351, 1998.

61. Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J and Wilson W: Safety, tolerance and pharmacokinetics of a small unilamellar liposomal formulation of Amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391-2398, 1998.

62. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC: Central nervous

system involvement in primary mediastinal large B-cell lymphoma. J Clin Oncol 17:2479-2485, 1999.

63. Kreitman RJ, Wilson WH, Robbines D, Margulies I, Stetler-Stevenson MA, Waldman

TA, Pastan I: Responses in refractory Hairy Cell leukemia to a recombinant immunotoxin. Blood 94:3340-3348, 1999.

13

64. Cowan KH, Moscow JA, Huang H, Zujewski J, O’Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, Leitman SF, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis: Paclitaxel chemotherapy following autologous stem cell transplantation and engraftment of hematopoietic cells transduced with retrovirus containing the multidrug resistance cDNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 5:1619-1628, 1999.

65. Wilson W: Clinical aspects and treatment in angioimmunoblastic T cell lymphoma

(AILD). In Clinical Implications of the R.E.A.L Classification. Mason DY and Harris NL, editors. Springer-Verlag, London, Publishers, 1999.

66. Wilson W: Clinical aspects and treatment options in nasal/nasal type lymphoma

(angiocentric lymphomas) and lymphomatoid granulomatosis. In Clinical Implications of the R.E.A.L Classification. Mason DY and Harris NL, editors. Springer-Verlag, London, Publishers, 1999.

67. Baris D, Kwak L, Rothman N, Wilson W, Manns A, Tarone RE, Hartge P: Blood

levels of organochlorines before and after chemotherapy among non-Hodgkin’s lymphoma patients. Cancer Epidemiol Biomarkers and Prev 9:193-197, 2000.

68. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson MA, Jaffe E, Giardina S,

Waldmann TA, Pastan I: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622-1636, 2000.

69. Wilson WH, Sorbara L, Figg WD, Month EK, Sausville E, Warren KE, Balis FM,

Bauer K, Raffeld M, Senderowicz AM, Monks A: Modulation of clinical drug resistance in a B-cell lymphoma patients by the protein kinase inhibitor 7-Hydroxystaurosporine (UCN-01): Presentation of a novel therapeutic paradigm. Clin Cancer Res 6:415-421, 2000.

70. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC,

Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma by gene expression profiling. Nature 403:503-511, 2000.

71. Little R, Gutierrez M, Wilson WH: Chemotherapy sensitization by rituximab:

Presentation of two case studies. Case Studies in Oncology 2:1-7, 2000.

72. Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause GL, Janik JE, Bramen VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ: Combination chemotherapy followed by a recombinant immunotoxin (anti-B4-

14

blocked ricin) in patients with indolent lymphomas: Results of a phase II study. Cancer J Sci Am 6:146-150, 2000.

73. Bishop PC, Rao VK, Wilson W: Burkitt’s lymphoma: Molecular pathogenesis and

treatment. Cancer Invest 18:574-583, 2000.

74. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH: The role of retreatment with a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8 year follow-up study of EPOCH. J Clin Oncol 18:3633-3642, 2000.

75. Little RF, Yarchoan R, Wilson WH: Systemic chemotherapy for HIV-associated

lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol 12:438-444, 2000.

76. Chabner BA, Wilson W, Supko J: Pharmacology and toxicity of antineoplastic

drugs. In William’s Hematology, 2001.

77. Wilson WH: Chemotherapy sensitization by rituximab: Experimental and clinical evidence. Semin Oncol 27:30-36, 2001.

78. Gutierrez ME, Grossbard M, Jaffe E, Chabner BA, Wilson WH: Dose-adjusted

EPOCH-Rituximab (EPOCH-R): An effective regimen in poor prognosis aggressive B-cell lymphoma. Biologic Therapy of Lymphoma 4:10-13, 2001.

79. Saif MW, Little RF, Hamilton M, Allegra CJ and Wilson WH: Reactivation of

chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: A care report and review of the literature. Ann Oncol 12:123-129, 2001.

80. Hegde U, Wilson WH: Gene expression profiling of lymphomas. Curr Oncol

Reports 3:243-249, 2001.

81. Jaffe ES, Wilson WH: Lymphomatoid Granulomatosis. Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, pg 185-187, 2001.

82. Leach FS, Gutierrez M, Pavlovich C, Wilson W: Lymphoma of the kidney: A case

of mistaken identity. Infections in Urology 14:46-48, 2001.

83. Little RF, Gutierrez M, Jaffe E, Pau A, Horne M, Masur H, Wilson W: HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA 285:1880-1885, 2001.

15

84. Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M, Wilson WH, Jaffe ES: Cutaneous lymphomatoid granulomatosis: Correlation of clinical and biological features. Am J Surg Pathol 25:1111-1120, 2001.

85. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson MA,

FitzGerald DJ, Pastan I: High complete remission rate in chemotherapy-resistant classic or variant Hairy Cell Leukemia induced by the anti-CD22 recombinant immunotoxin BL22. New Engl J Med 345:241-247, 2001.

86. Pickarz RL, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner

ML, Atlimus R, Bases SE: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma. Blood 98:2865-2868, 2001.

87. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L,

Pickeral O, Powell J, Botstein D, Byrd JC, Grever MR, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM: Relation of gene expression phenotype to immunoglobulin mutation genotype in Chronic Lymphocytic Leukemia. J Exp Med 194:1639-1647, 2001.

88. Gill R, Van Waes C, Kass E, Wilson W: Lymphomas of the head and neck; In

Otolaryngology and Facial Plastic Surgery. Emedicine 2:10-15, 2001.

89. Wilson WH, Gutierrez M, O’Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML: Role of rituximab and chemotherapy in aggressive B-cell lymphomas: A preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29:41-47, 2002.

90. Wilson WH, Grossbard ML, Pittaluga, S, Cole D, Pearson D, Drbohlav N,

Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F: Dose-adjusted EPOCH chemotherapy in untreated large B-cell lymphomas: A novel pharmacodynamic approach with high efficacy. Blood 99:2685-2693, 2002.

91. Rosenwald A, Wright G, Campo E, Chan WC, Fisher RI, Gascoyne R, Muller-

Hermelink HK, Smeland EB, Staudt LS, for the Lymphoma/Leukemia Molecular Profiling Project. Author list by Lymphoma/Leukemia Molecular Profiling Project (LLMPP) Consortium Center: Rosenwald A, Wright G, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Powell J, Duffey PL. Longo DL, Wilson WH, Jaffe E, Simon R, Klausner RD, Staudt LM et al. Molecular Diagnosis and Clinical Outcome Prediction in Diffuse Large B-cell Lymphoma. N Engl J Med 346:1937-1947, 2002.

92. Gutierrez ME, Wilson WH: Salvage chemotherapy of non-Hodgkin’s lymphomas.

In Malignant Lymphoma. B.C. Decker, Inc, London. Salvage Chemotherapy of Non-Hodgkin’s Lymphoma. P 289-300.

16

93. Hegde U, Wilson WH, White T, Cheson BD: Rituximab Treatment of Refractory Fludarabine-associated Immune Thrombocytopenia in Chronic Lymphocytic Leukemia. Blood 100:2260, 2002.

94. Staudt L, Wilson WH: Focus on Lymphoma. Cancer Cell 2:363, 2002.

95. Bryant-Greenwood PK, Sorbara L, Filie AC, Little R, Yarchoan R, Wilson W,

Raffeld M, Abati A: Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi’s Sarcoma, Castleman’s Disease and recurrent pleural effusions. Mod Path 16:145, 2003.

96. Little RF, Pittaluga S, Drbohlav N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini

G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, and Wilson WH: Highly effective treatment of acquired immunodeficiency syndrome related lymphoma with dose adjusted EPOCH: Impact of anti-retroviral therapy suspension and tumor biology. Blood 101:4653, 2003.

97. Leonard GD, Hege U, Butman JH, Jaffe ES, Wilson WH: Extraocular muscle

palsies in subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol 21:2993, 2003.

98. Wiestner A, Rosenwald A, Barry T, Wright G, Davis RE, Henrickson SE, Zhao H,

Ibbotson RE, Orchard JA, Davis Z, Steterler-Stevenson M, Raffeld M, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 101:4944, 2003.

99. Little RF, Wilson WH: Update on the pathogenesis, diagnosis and therapy of

AIDS-related lymphoma. Curr Infect Dis Rep 5:176, 2003.

100. Rosenwald A, Wright G, Weistner A, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne R, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L. Henrickson S, Yang L, Powell J, Wilson WH, Jaffe E, Simon R, Klausner RD, Montserrat E, López-Guillermo A, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The Proliferation Gene Expression Signature is a Quantitative Integrator of Oncogenic Events that Predicts Survival in Mantle Cell Lymphoma. Cancer Cell 3:185, 2003.

101. Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-

Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. BBMT 9:162, 2003.

17

102. Nguyen JD, Carrasquillo JA, Little RF, Ryan QC, Wilson W, Chen CC. Fluoro-

deoxyglucose positron emission tomography in the presence of cardiac metastases. Clin Nucl Med 28:979, 2003.

103. Wilson WH: Commentary: DNA Microarrays in Lymphoid Malignancies. Oncology

17:1759, 2003.

104. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, López-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198:851, 2003.

105. Murdock J, Jaffe ES, Wilson WH, McManus DT et al: Aggressive natural killer cell

leukemia/lymphoma: Care report, use of telesynergy and review of the literature. Leukemia and Lymphoma 45:1269, 2004.

106. Hegde U, Wilson WH: New Treatment Strategies in Chronic Lymphocytic

Leukemia. In Treatment of Chronic Lymphocytic Leukemias. In Chronic Lymphocytic Leukemia: Pages 315-328. Editor Faguet G.B, Human Press, Totowa, New Jersey. 2004.

107. Jaffe ES and Wilson WH: Grey zone, synchronous and metachronous lymphomas:

Diseases at the interface of Hodgkin and non-Hodgkin lymphomas. Non-Hodgkin’s Lymphomas. Eds. Mauch PM, Armitage JO, Coiffier B, Dalla-Favera R and Harris NL. Lippiincott Williams and Wilkins Publisher, Philadelphia, 2004.

108. Dunleavy K, Staudt LM, Wilson WH: Clinical Applications of Molecular Profiling in

Lymphomas. Progress in Oncology. Eds. Devita VT, Hellamn S and Rosenberg SZ. Jones and Bartlett Publishers, Sudbury, Massachusetts, 2004.

109. Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Drbohlav N,

Gutierrez M, Waldmann TA, Wilson WH: Serum soluble interleukin-2 receptor levels are elevated in patients with anaplastic large cell lymphoma. Blood 104:3355, 2004.

110. Rosenwald A, Chuang EY, Davis RE, Wiestner A. Alizadeh AA, Botstein D, Brown

PO, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM: Fludarabine Treatment of Chronic Lymphocytic Leukemia Patients Induces a p53-Dependent Gene Expression Response. Blood 104:1428, 2004.

18

111. Mattu R, Sorbara1 L, Filie A, Little R, Wilson W, Raffeld M, Abati A: Utilization of Polymerase Chain Reaction on Archival Cytologic Material: a Comparison with Fresh Material with Special Emphasis on CSFs. Mod Path 17:1295, 2004.

112. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI,

Braziel RM, Grogan TM. Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp P, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM: Survival Following Diagnosis of Follicular Lymphoma is Predicted by Molecular Features of Non-malignant Tumor-infiltrating Immune Cells. New Eng J Med 351:2159, 2004.

113. Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM,

Wilson WH: Non-Hodgkin’s lymphoma in Job’s syndrome: A case report and literature review. Leukemia and Lymphoma 45:2521, 2004.

114. Little R, Gutierrez M, Wilson WH: Non-Hodgkin’s Lymphoma. Clinical Hematology,

Elsevier, 2004.

115. Wilson W, Supko J: Pharmacology and Toxicity of Anti-Neoplastic Agents. Hematology, eds. Williams, 2004.

116. Wilson WH. Principals of Treatment in “The Lymphomas”. 2nd Edition. Editors:

Canellos G, Lister TA, and Young B. Saunders. 2004.

117. Chabner BA, Wilson W, Supko J: Pharmacology and Toxicity of Anti-Neoplastic Agents. Goodman and Gilman, 2004.

118. Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan CD.

Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma. Transfusion 44:1679, 2004.

119. Grube M, Rezvani M, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ,

Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA. Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. Clin Ca Res 10:1047, 2004.

120. Lunning MA, Zenger VE, Dreyfuss R, Stetler-Stevenson M, Rick ME, White TA,

Wilson WH, Marti GE: Albumin enhanced morphometric image analysis in CLL. Cytometry B Clin Cytom 57:7, 2004.

121. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe

ES, Abati A, Stetler-Stevenson MA, Wilson WH: High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive

19

B-cell lymphomas at risk of central nervous system involvement: The role of flow cytometry versus cytology. Blood 105:496, 2005.

122. Gutierrez M, Little R, Wilson WH: Non-Hodgkin’s Lymphoma. Bethesda Handbook

of Clinical Oncology. Second edition. Editors Abraham J, Allegra CJ and Gulley J. Lippincott Williams and Wilkins, 28:357-375, 2005.

123. Abraham J, Wilson W, Jaffe E: Hodgkin’s Lymphoma. Bethesda Handbook of

Clinical Hematology. Editors Rodgers GP and Young NS. Lippincott Williams and Wilkins, 15:186-198, 2005.

124. Little RF, Gutierrez M, Wilson WH. Non-Hodgkin’s Lymphoma. Bethesda

Handbook of Clinical Hematology. Editors Rodgers GP and Young NS. Lippincott Williams and Wilkins, 16:199-220, 2005.

125. Patsalides A, Hegde U, Butman JA, Jaffe E, NJ Patronas NJ, Wilson WH: Central

nervous system radiological abnormalities in lymphomatoid granulomatosis. Radiology 237:265-273, 2005.

126. Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright

G, Kwak L, Gress R, Tosato G, Wilson WH. B-cell Recovery Following Rituximab-Based Therapy Is Associated with Perturbations in Stromal Derived Factor-1 and Granulocyte Homeostasis. Blood 106:795, 2005.

127. Dunleavy K, Wilson WH: Lymphomas in American College of Physicians Medicine.

Section 12, 2005.

128. Neelapu SS, Kwak LW, Kobrin CB, Janik J, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg S, Gress R, Hakim F, Wilson WH: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 11:986-991, 2005.

129. Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W, Stetler-

Stevenson MA. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom. 67:6-12, 2005.

130. Kreitman RJ, Squires DR, Stetler-Stevenson AM, Noel P, FitzGerald DJP, Wilson

WH and Pastan I. Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients with B-cell Malignancies. J Clin Oncol 23:6719-6729, 2005.

131. Fu K, Weisenburger DD, Greiner TC, Dave S, Chiorazzi M, Wright G, Gesk S,

Siebert R, De Jong D, Jaffe ES, Delabie J, Ott G, Wilson W, Braziel RM, Dave BJ, Sanger WG, Smith LM, Müller-Hermelink HK, Campo E, Gascoyne RD, Rosenwald A, Staudt LM, and Chan WC: Cyclin D1-Negative Mantle Cell

20

Lymphoma: A Gene Expression Profiling, Genetic and Clinicopathological Study. Blood 106:4315, 2005.

132. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-

Sportes C, Gress RE, Bishop MR: Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplantation in Chemotherapy-Refractory Non-Hodgkin’s Lymphoma. Biol Blood Marrow Transplant 11:593, 2005.

133. Wilson WH: R-CHOP Strikes Again with Survival Benefit in Follicular Lymphoma:

Where do we go from here? Blood 106: 3678-3679, 2005.

134. Wilson WH: Long Term Results of the R-CHOP Study in Elderly Patients with DLBCL. Am J Oncology Rev 4:650-650, 2005.

135. Aurran-Schleinitz T, Telford W, Perfetto S, Caporaso N, Wilson W, Stetler-

Stevenson MA, Zenger VE, Abbasi F, Marti GE. Identification of a new monoclonal B-cell subset in unaffected first-degree relatives in familial chronic lymphocytic leukemia. Leukemia 19:2339-2341, 2005.

136. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X,

Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A: Diffuse Large B Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction. Blood 106:3183, 2005.

137. Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P,

Rosenberg J, Wilson WH, Robinson MR: The Pharmacokinetics of Rituximab following an Intravitreal Injection. Exp. Eye Res. 82:760, 2006.

138. Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ: Radiofrequency

Ablation of Lymphoma. Blood 107:1624, 2006.

139. Chabner BA, Amrein PC, Druker B, Michaelson MD, Mitsiades CS, Goss PE, Ryan DP, Ramachandra S, Richardson PG, Supko JG and Wilson WH: Chemotherapy of Neoplastic Diseases: Antineoplastic Agents in Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Eleventh edition. Editors Brunton LL, Lazo JS and Parker. McGraw-Hill, New York. 51:1315-1404, 2006.

140. Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F, Tretler J,

Fleisher T, Puck JM, Wilson W, Jaffe ES, Avila N, Chen CC, Straus SE. Fluorodeoxyglucose Positron Emission Tomography (FDG PET) for Monitoring Lymphadenopathy in the Autoimmune Lymphoproliferative Syndrome (ALPS). Amer J Heme 81:81, 2006.

21

141. Schinstine M, Filie AC, Wilson W, Stetler-Stevenson MA, and Abati A: Detection of Malignant Hematopoietic Cells in Cerebral Spinal Fluid Previously Diagnosed as Atypical or Suspicious. Cancer 108:157, 2006.

142. Dunleavy K, Wilson WH: The Case for Rituximab in AIDS-Related Lymphoma.

Blood 107:3014-3015, 2006.

143. Dave SS, Fu K, Wright GE, Lam LT, Greiner TC, Weisenburger DD, Kluin P, Boerma EJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Vose J, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM for the Leukemia Lymphoma Molecular Profiling Project: Molecular Diagnosis of Burkitt Lymphoma. N Engl J Med 354:2431, 2006.

144. Kreitman RJ, Wilson WH, Pastan I: Complete Remissions of Purine Analog-

Resistant Hairy Cell Leukemia Induced by the Anti-CD22 Recombinant Immunotoxin BL22. Trends in Diphtheria Research, Nova Science Publishers, Inc, Hauppauge, New York, 2006.

145. Bernstein WB, Little RF, Wilson WH, Yarchoan R: AIDS-Related Malignancies in

the HAART Era. Int. J. Hematol 83:3, 2006.

146. Wayne A, Wilson WH: Burkitt and Lymphoblastic Lymphoma. Lymphoma: Diagnosis and Treatment. Editors Marcus R, Sweetenham J and Williams M. Cambridge University Press, Cambridge, 2006.

147. Dunleavy K, Wilson WH: Primary Intraocular Lymphoma: Current and Future

Perspectives. Leukemia and Lymphoma 47:1726, 2006.

148. Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M. International Central Nervous System & Ocular Lymphoma Workshop: Recommendations for the future. Ocul Immunol Inflamm. 14:139, 2006.

149. Wilson WH. Drug Resistance in Diffuse Large B-cell Lymphoma. Semin Heme

43:230, 2006.

150. Ise T, Nagata S, Kreitman RJ, Wilson WH, et al: Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21:169, 2007.

151. Dunleavy K, Davis E, Landgren O, Staudt LM, Wilson WH: BCL-6 and Rituximab

in Diffuse Large B-cell Lymphoma: Where are we? Blood 109:843, 2007.

22

152. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, et al: A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy. Clin Cancer Res 13:958, 2007.

153. Kelloff GJ, Sullivan DM, Wilson W, et al: FDG-PET Lymphoma Demonstration

Project Invitational Workshop. Academic Radiology 14:330, 2007.

154. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES and Staudt LM for theLymphoma/Leukemia Molecular Profiling Project: Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. Blood 109:4599, 2007.

155. Dunleavy K, Wilson WH: Angioimmunoblastic T-cell Lymphoma: Immune

Modulation as a Therapeutic Strategy. Leukemia and Lymphoma 48:449, 2007.

156. Dunleavy K, Wilson WH, Jaffe ES: Angioimmunoblastic T-cell Lymphoma (AILT): Pathobiological Insights and Clinical Implications. Curr Opin Hematol 14:348, 2007.

157. Dunleavy K, Staudt LM, Wilson WH: The Bcl-2 Biomarker in the Era of Molecular

Diagnosis of Diffuse Large B-cell Lymphoma. Leukemia and Lymphoma 48:1061, 2007.

158. Dunleavy K, Wilson WH: Diagnosis and Treatment of Non-Hodgkin Lymphoma

(Aggressive). Hoffman Text Book of Hematology, 2007.

159. Wilson WH and Armitage J: Non-Hodgkin’s Lymphoma. Clinical Oncology, Ed Abeloff et al.

160. Wilson WH: International consensus recommendations on the flow cytometric

immunophenotypic analysis of hematolymphoid neoplasia. Cytometry B Clin Cytom. 2007;72 Suppl 1:S2.

161. Wilson WH: 2006 Bethesda International Consensus recommendations on the

flow cytometric immunophenotypic analysis of hematolymphoid neoplasia. Editorial, 72B:S2, 2007.

162. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 26:4124-30, 2008.

23

163. Hwang S, Janik J, Jaffe ES, Wilson WH: Cutaneous T-cell Lymphomas. Lancet 371:945, 2008.

164. Buske C, Gisselbrecht C, Gribben J, Letai T, Mclaughlin P, Wilson W. Refining the

treatment of follicular lymphoma. Leukemia and Lymphoma 49:18-26, 2008.

165. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A and Rader C: Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia. Clin Cancer Res 14:396, 2008.

166. Wilson WH, Dunleavy K, Pittaluga S, et al: Dose-Adjusted EPOCH-Rituximab in

Untreated Germinal Center and Post-Germinal Center Diffuse Large B-cell Lymphoma. J Clin Oncol 26:2717-2724, 2008.

167. Ahmad E, Steinberg SM, Goldin L, Hess CJ, Caporaso N, Kreitman RJ, Wiestner

A, Wilson W, White T, Marti G, Stetler-Stevenson MA: Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. Cytometry B Clin Cytom. 74:221-226, 2008.

168. Shanti RM, Torres-Cabala CA, Jaffe ES, Wilson WH, Brahim JS. Lymphomatoid

Granulomatosis With Involvement of the Hard Palate: A Case Report. J Oral Maxillofac Surg. 66:2161-2163, 2008.

169. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, Quijano S,

Stetler-Stevenson MA, Subira D, Wilson W. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid. Current Protocols in Cytometry 6.25.1-6.25.16, 2008.

170. Pittaluga S, Wilson WH, Jaffe ES: Lymphomatoid Granulomatosis. WHO

Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours. Editors Swerdlow SH, Campo E, Harris NL, et al. International Agency for Research on Cancer, Lyon, 2008. Pages 247-249.

171. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, Quijano S,

Stetler-Stevenson M, Subira D, Wilson W. Flow Cytometric Immunophenotyping of Cerebrospinal Fluid. Curr Protoc Cytom. 2008 Jul; Chapter 6:Unit 6.25.

172. O’Mahoney D, Peikarz RL, Bandettini WP, Arai AE, Wilson W, Bates SE. Cardiac

involvement with lymphoma: a review of the literature. Clin Lymphoma Myeloma. 8:249-52, 2008.

173. Rizzo K, Stetler-Stevenson M, Wilson W, Yuan CM: Novel CD19 expression in a

peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation. Cytometry B Clin Cytom. 76:142-9, 2008.

24

174. Young KH, Leroy K, Møller MB, Colleoni GWB, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC: Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 112:3088-3098, 2008.

175. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri

SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 111:5496-504, 2008.

176. Hoover SE, Kawada J, Wilson W, Cohen J: Oropharyngeal shedding of Epstein-

Barr virus in the absence of circulating B cells. J Infect Dis. 198:318-323, 2008.

177. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink H-K, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM. Stromal Gene Signatures in Large-B-Cell Lymphomas. N Engl J Med 359:2313-2323, 2008.

178. Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, Keyvanfar K, Gibellini F,

Valdez J, Samsel L, McCoy JP Jr, Wilson W, Pittaluga S, Wiestner. Lenalidomide Induced Upregulation of CD80 on Tumor Cells Correlates with T-cell Activation, the Rapid Onset of a Cytokine Release Syndrome and Leukemic Cell Clearance in Chronic Lymphocytic Leukemia. Haematologica. 94:1266-73, 2009.

179. Dunleavy K, Pittaluga S, Czuczman M, Dave S, Wright G, Grant N, Shovlin M,

Jaffe ES, Janik J, Staudt LM, Wilson WH: Differential Efficacy of Bortezomib Plus Chemotherapy Within Molecular Subtypes of Diffuse Large B Cell Lymphoma. Blood. 113:6069-76, 2009.

180. Kochenderfer JN, Feldman SA, Zhao Y, Xu Y, Black MA, Morgan A, Wilson WH,

Rosenberg SA. Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor. J Immunother. 32:689-702, 2009.

181. Kreitman R, Stetler-Stevenson MA, Margulies I, Noel P, FitzGerald DJP, Wilson

WH, Pastan I. Phase II Trial Of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) In Patients With Hairy Cell Leukemia. J Clin Oncol. 27:2983-90, 2009.

25

182. Little RF, Wilson WH. Non-Hodglin’s Lymphoma. The Bethesda Handbook of

Clinical Hematology, edited by Drs. Rodgers and Young. 2009.

183. Dunleavy K, Wilson WH: HIV-Associated Lymphoid Neoplasms. The Lymphoid Neoplasms, 3rd Edition. Editor Ian Magrath. Hodder Arnold, London, 2009.

184. Jaffe ES, Wilson WH: Borderlines between Pathologic Entities: Composite

Lymphomas. The Lymphoid Neoplasms, 3rd Edition. Editor Ian Magrath. Hodder Arnold, London, 2009.

185. Jiang L, Yuan C, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA,

Stetler-Stevenson M. Variable CD52 Expression in Mature T Cell and NK Cell Malignancies: Implications for Alemtuzumab Therapy. Br J Haematol. 45:173-9, 2009.

186. Buske C, Gisselbrecht C, Gribben J, Letai T, Mclaughlin P, Wilson W: Refining the

treatment of follicular lymphoma. Leuk and Lymphoma 48:18, 2009.

187. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica 94:1259-65, 2009.

188. Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD,

Vose JM, Armitage JO, Weisenburger DD; International Peripheral T-Cell Lymphoma Project. The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol. 20:715-21, 2009.

189. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic tools for

neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol. 36(4 Suppl 2):S35-45, 2009.

190. Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O.

Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica. 94:1259-65, 2009.

191. Landgren O, Dunleavy K, Wilson WH. Re: Rituximab maintenance for the

treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. Letter. J Natl Cancer Inst. 101:1287-8, 2009.

192. Tay K, Dunleavy K, Wilson WH. Targeting HLA-DR. Leuk and Lymphoma

50:1911-1913, 2009.

26

193. Jiang L, Abati AD, Wilson W, Stetler-Stevenson M, Yuan C. Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up. Int J Clin Exp Pathol. 15:110-116, 2009.

194. Davis RE, Ngo V, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H,

Lamy L, Zhao H, Yang Z, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang J, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink K, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Wilson W, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B-cell receptor signaling in diffuse large B-cell lymphoma. Nature 463:88-94, 2010.

195. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg

SM, Yarchoan R, Jaffe ES, Wilson WH. The Role of Tumor Histogenesis, FDG-PET and Short Course EPOCH with Dose Dense Rituximab (SC-EPOCH-RR) in HIV-Associated Diffuse Large B-cell Lymphoma. Blood 115:3017-3024, 2010.

196. Tay K, Dunleavy K, Wilson WH: Novel agents for B-cell non-Hodgkin’s lymphoma:

Science and promise. Blood Rev 24:69-82, 2010.

197. Roschewski M, Wilson WH. Biology and Management of Rare Primary Extranodal T-cell Lymphomas. Oncology 24:94-100, 2010.

198. Leshchenko V, Kuo P, Shaknovich R, Yang DT, Gellen T, Pêche H, Yu Y,

Remache Y, Weniger M, Rafiq S, Suh S, Goy A, Wilson W, Verma A, Muthusamy N, Kahl B, Byrd J, Wiestner A, Melnick A, Parekh S. Genome wide DNA Methylation Analysis reveals novel targets for drug development in Mantle cell lymphoma. Blood 116:1025-1034. 2010.

199. Dunleavy K, Tay K, Wilson WH. Rituximab Associated Neutropenia. Semin Heme

47:180-186, 2010.

200. Moriyama B, Falade O, Leung J, Penzak SR, Jingo CJ, Huang X, Henning SA, Masur H, Wilson WH, Walsh TJ. Prolonged Half-life of Voriconazole in a CYP2C19 Homozygous Poor Metabolizer Receiving Vincristine Chemotherapy: Avoiding a Serious Adverse Drug. Ann Pharmacother 44:929-935, 2010.

201. Dunleavy K, Wilson WH. Role of Molecular Subtype in Predicting Outcome of

AIDS-Related Diffuse Large B-cell Lymphoma. Letter. J Clin Oncol 28:260, 2010.

202. Shao H, Xi L, Raffeld M, Pittaluga S, Dunleavy K, Wilson WH, Spector N, Milito C, Morais JC, Jaffe ES. Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression. Am J Surg Pathol. 34:1425-35. 2010.

27

203. Dunleavy K, Wilson WH. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma. Leuk Lymphoma. 51:1347-1350. 2010.

204. Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates

SE.New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies. Clin Cancer Res. 2010 Dec 1;16(23):5608-17.

205. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M,

Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood 116:4099-4102. 2010.

206. Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH. The value of positron

emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 51 Suppl 1:28-33. 2010.

207. Dunleavy K, Wilson WH. Chapter 88: HIV-Associated Lymphoid Neoplasms. The

Lymphoid Neoplasms, 3rd Edition. Edited by Ian Magrath. (Hodder Arnold). Publication Spring 2010.

208. Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA. Novel

disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma 51 Suppl 1:1-10. 2010.

209. Wilson WH, O’Connor OA, Czuczman MS et al. Navitoclax, a targeted high-affinity

inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11:1149-1159. 2010.

210. Grant C, Wilson WH, Dunleavy K. Neutropenia associated with rituximab therapy.

Curr Opin Hematol. 2010 Nov 22. [Epub ahead of print].

211. Savan R, Reynolds DA, McFarland AP, Feigenbaum L, Ramakrishnan K, Shirota H, Klinman DM, Dunleavy KM, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA. Ectopic expression of IL-22R1 on lymphocytes results in systemic inflammation in mice: A model for ALK+

anaplastic large cell lymphoma. Blood

117:575-584. 2011.

212. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari S, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson MA, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A. The lymph node microenvironment promotes B-cell receptor signaling, NF-{kappa}B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563-574. 2011.

28

213. Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti E, Chapman CM, Mo C, Stennett L, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy K, Wilson WH, Staudt LM, Wiestner A. Bortezomib resistance in Mantle Cell Lymphoma is associated with plasmacytic differentiation. Blood, 117:542-552. 2011.

214. Dunleavy K, Wilson WH. Diagnosis and Treatment of Non-Hodgkin Lymphoma

(Aggressive). Hoffmann Hematology: Basic Principles and Practices 5th Edition 2011. (Elsevier Saunders).

215. Dunleavy K, Wilson WH. Chapter XI. Malignant Lymphomas. American College of

Physicians (ACP) Medicine Textbook. Published 2011.

216. Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA and Jaffe ES. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series.Blood 117:1447-1452. 2011.

217. Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP,

Press OW, Wilson WH. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2011 Jan;52(1):24-33.

218. Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, Adams

LG, Hewitt SM, Wilson WH, Pittaluga S, Meltzer PS, Staudt LM, Emmert-Buck MR, Jaffe ES. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin’s lymphoma and primary mediastinal large B-cell lymphoma. Haematologica 96:558-566. 2011.

219. Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, Dunleavy K, Pittaluga

S, Jaffe ES. Coexisting and Clonally Identical Classic Hodgkin Lymphoma and Nodular Lymphocyte Predominant Hodgkin Lymphoma. Am J Surg Pathol 35:767-772. 2011.

220. Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, JJingo C, Huang X, Henning

SA, Wilson WH, Walsh TJ. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses. 2011 Nov;54(6):e877-9.

221. Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk Lymphoma. 2011 Jun;52 Suppl 2:82-6.

222. Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES.Primary

mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep. 2011 Sep;6(3):157-63.

29

223. Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation. Cytometry B Clin Cytom. 2011 Sep;80(5):309-17.

224. Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH,

Wiestner A, Stetler-Stevenson MA, Marti GE. Methodological comparison of two anti-ZAP-70 antibodies. Cytometry B Clin Cytom. 2011 Sep;80(5):300-8.

225. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S,

Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 2;117(22):5835-49.

226. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan

KA, Rüdiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011 Mar 24;117(12):3402-8.

227. Dunleavy K, Wilson WH. Differential role of BCL2 in molecular subtypes of diffuse

large B-cell lymphoma. Clin Cancer Res. 2011 Dec 15;17(24):7505-7.

228. Eberle FC, Salaverria I, Steidl C, Summers TA Jr, Pittaluga S, Neriah SB, Rodriguez-Canales J, Xi L, Ylaya K, Liewehr D, Dunleavy K, Wilson WH, Hewitt SM, Raffeld M, Gascoyne RD, Siebert R, Jaffe ES Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.. Mod Pathol. 2011 Dec;24(12):1586-97.

229. Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES,

Dunleavy K, Janik JE, Steinberg SM, Wilson WH.Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. Leuk Lymphoma. 2011 Dec;52(12):2284-92.

230. Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ,

Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res. 2011. 17:5101-5112.

231. Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S,

Keyvanfar K, Lee E, Wilson W, Wiestner A. Activation of CD44, a receptor for

30

extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma. 2011. 52:1758-1769.

232. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I,

Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012. 119:2709-2720.

233. Dunleavy K, Kass E, Wilson WH. Emedicine. Otolaryngology and Facial Plastic

Surgery. Lymphomas of the head and neck. 2012.

234. Dunleavy K, Grant C, Wilson WH. Lymphomas (Emerging Cancer Therapeutics V3 12 by Sweetenham (Demos Medical) Published 11/2012. Chapter 5. ‘Novel Pathways and Therapeutic Strategies for Aggressive B-Cell Lymphomas’.

235. Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells

with an immunotoxin against ROR1. MAbs. 2012. 4::349-361

236. Roschewski M, Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol. 2012. 25:75-89.

237. Eberle FC, Song JY, Xi L, Raffeld M, Harris NL, Wilson WH, Pittaluga S, Jaffe ES.

Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Am J Surg Pathol. 2012. 36:716-725.

238. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M,

Fitzgerald DJ, Lechleider R, Pastan I.Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. J Clin Oncol. 2012. 30:1822-1828.

239. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012.

119:3245-3255.

240. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED; for the Cancer Leukemia Group B A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.. Haematologica. 2012. 97:758-765.

241. Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH,

Wiestner A, Stetler-Stevenson MA, Marti GE.Combined normal donor and CLL: Single tube ZAP-70 analysis. Cytometry B Clin Cytom. 2012. 82:67-77.

31

242. Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR: Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol. 2012. 30:830-836.

243. Roschewski M, Dunleavy K, Wilson WH. Diffuse large B cell lymphoma: molecular

targeted therapy. Int J Hematol. 2012. 96:552-561.

244. Roschewski M, Wilson WH. Lymphomatoid Granulomatosis. Cancer J. 2012. 18:469-474.

245. Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown

JR, Letai A. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012. 120:3501-9.

246. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V,

Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A, Stamatopoulos K, Beà S, Campo E. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012. 72:5307-5316.

247. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012. 490:116-120.

248. Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH. Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma? Curr Hematol Malig Rep. 2012. 7:241-247.

249. Dunleavy K, Roschewski M, Wilson WH. Lymphomatoid granulomatosis and other

Epstein-Barr virus associated lymphoproliferative processes. Curr Hematol Malig Rep. 2012. 7:208-215.

250. Dunleavy K, Grant C, Wilson WH. Primary Mediastinal B-Cell Lymphoma.

Lymphoma Diagnosis and Treatment (Current Clinical Oncology). (Humana Press). Edited by Younes/Coiffier. 2013.

32

251. Mo C, Roschewski M, Dunleavy K, Wilson WH. Chapter 28 Non-Hodgkin lymphoma. Bethesda Handbook of Clinical Oncology 4th Edition. Lippincott, Williams and Wilkins. 2013.

252. Dunleavy K, Grant C, Wilson WH. Using biologic predictive factors to direct

therapy of diffuse large B-cell lymphoma. Therapeutic Advances in Haematology. February 2013. 4:43-57.

253. Dunleavy K, Wilson WH. Chapter 81. Diagnosis and Treatment of Diffuse-Large B-

Cell lymphoma and Burkitt lymphoma. Hoffman Hematology: Basic Principles and Practices 6th Edition 2013. (Elsevier Saunders).

254. Wilson W, Schenkein D, Jernigan C, Woodcock J, Schilsky R. Re-evaluating the

Accelerated Approval Process for Oncology Drugs. Clin Cancer Res. 2013. 19:2804-2809.

255. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM,

Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-Adjusted-EPOCH-R Therapy in Primary Mediastinal B-cell Lymphoma. N Eng J Med 2013. 368:1408-1416.

256. Kantarjian H, Wilson W, Ravandi F, Estey. Decitabine in older adults with acute

myeloid leukemia: why was the dream broken? J Clin Oncol 2013. 31:1795-1796.

257. Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V, Hartmann E, Salaverria I, Beà S, Martín-Subero JI, Rosenwald A, Ott G, Wiestner A, Wilson WH, Campo E, Hernández L. microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics. Clin Cancer Res. 2013. 19:3121-3129.

258. Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson

WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Bcl-2 level as a biomarker for 13q14 deletion in CLL. Cytometry B Clin Cytom. 2013. 84:237-247.

259. Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B, Lee E, Marti G, Wilson WH,

Taylor RP, Wiestner A. Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia. Haematologica. 2013. 98:1259-1263.

260. Lai C, Wilson W. T-cell lymphoma. Best Pract Res Clin Haematol. 2013. 26:1.

261. Bax HI, Freeman AF, Anderson VL, Vesterhus P, Laerum D, Pittaluga S, Wilson

WH, Holland SM. B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency. J Clin Immunol. 2013. 33:1062-1066.

33

262. Wilson WH, Grant C, Dunleavy K. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013. 369:283-284.

263. Dunleavy K, Wilson WH. Implications of the shifting pathobiology of AIDS-related

lymphoma. J Natl Cancer Inst. 2013. 105:1170-1171.

264. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, Buggy JJ, Elias L. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013. 122:2412-2424.

265. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM,

Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013. 122:3251-3262.

266. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 2013. 19:6313-6321.

267. Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E,

Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Di Croce L, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013. 110:18250-18255.

268. Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian

JJ, Wilson WH, Van Etten RA. Emerging therapeutic paradigms to target the dysregulated JAK/STAT pathways in hematological malignancies. Leuk Lymphoma. 2014. 55:1968-1979.

269. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment

approaches in the molecular era. Nat Rev Clin Oncol. 2014. 11:12-23.

270. Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013. 369:1915-1925.

34

271. Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M. Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res. 2013. 19:6873-6881.

272. Wilson WH. Treatment strategies for aggressive lymphomas: what works?

Hematology Am Soc Hematol Educ Program. 2013. 584-590.

273. Roschewski M, Dunleavy K, Wilson WH. Moving Beyond R-CHOP for Diffuse Large B-cell Lymphoma. Leuk Lymphoma. 2014 Jan 20. [Epub ahead of print].

274. Wilson WH, Bromberg JEC, Stetler-Stevenson M, Steinberg SM, Martin-Martin L,

Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A. The Outcome of Diffuse Large B-cell Lymphoma and Burkitt Lymphoma at Risk of Leptomeningeal Disease. Haematologica 2014. 99:1228-1235.

275. Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM,

Roschewski M, Staudt LM, Jaffe ES, Dunleavy K. A prospective study of mediastinal Gray Zone Lymphoma. Blood 2014. 124:1563-1569.

276. Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli

U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica 2014 99:1731-1737.

277. Mena E, Lindengerg ML, Turkbey BI, Shih J, Logan J, Adler S, Wong K, Wilson W,

Choyke PL, Kurdziel KA. A pilot study of the value of 18F-Fluoro-Deoxy-Thymidine PET/CT in predicting viable lymphoma in residual 18F-FDG avid masses after completion of therapy. Clin Nucl Med 2014 39:874-881.

278. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson

RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014. 124:1473-1480.

279. Tsai HT, Pfeiffer RM, Warren J, Wilson W, Landgren O. The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2015 56:682-687.

280. Dunleavy K, Wilson WH. Appropriate management of molecular subtypes of

diffuse large B-cell lymphoma. Oncology 2014. 28:326-334.

35

281. Roschewski M, Manasanch EE, Wilson WH. Management of heavy chain diseases: the challenges of biologic heterogeneity. Oncology 2014. 28:63-65.

282. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, Shovlin

M, Jaffe ES, Staudt LM, Lai C, Steinberg SM, Chen CC, Zheng J, Willis TD, Faham M, Wilson WH. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015. 16:541-549.

283. Roschewski M, Wilson WH. Cracking the diverse biologic code of diffuse large B-cell lymphoma. Semin Hematol. 2015 52:55-65

284. Leshchenko VV, Kuo PY, Jiang Z, Weniger MA, Overbey J, Dunleavy K, Wilson

WH, Wiestner A, Parekh S. Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma. Oncotarget. 2015 6:27332-27342.

285. Moraitis AG, Freeman LA, Shamburek RD, Wesley R, Wilson W, Grant CM, Price

S, Demosky S, Thacker SG, Zarzour A, Hornung RL, Pucino F, Csako G, Yarboro C, McInnes IB, Kuroiwa T, Boumpas D, Rao VK, Illei GG, Remaley AT. levated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency. J Clin Lipidol. 2015 9:81-90.

286. Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma and mediastinal

gray zone lymphoma: do they require a unique therapeutic approach? Blood. 2015. 125:33-39.

287. Song JY, Pittaluga S, Dunleavy K, Grant N, White T, Jiang L, Davies-Hill T,

Raffeld M, Wilson WH (co-senior author), Jaffe ES. Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol. 2015 39:141-156.

288. Dunleavy K, Roschewski M, Wilson WH. Precision treatment of distinct molecular

subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype. Clin Cancer Res. 2014 20:5182-5193.

289. Wilson WH, Young RM, Schmitz R, et al. Targeting B Cell Receptor Signaling with

Ibrutinib in Diffuse Large B Cell Lymphoma. Nat Med 2015 21:922-926.

290. Gharwan H, Lai C, Grant C, Dunleavy K, Steinberg SM, Shovlin M, Fojo T, Wilson WH. Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas. Leuk Lymphoma 2016 57:1616-1624.

291. Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C,

Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ,

36

Dunleavy K. Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 2016, 101:531-540.

292. Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, Melnick A, Grant C, Roschewski M, Navarro A, Beà S, Pittaluga S, Dunleavy K, Wilson WH, Wiestner A. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood 2016, 128:82-92.

293. Roschewski M, Staudt LM, Wilson WH. Dynamic monitoring of circulating tumor

DNA in non-Hodgkin lymphoma. Blood 2016 127:3127-32.

294. Barta SK, Joshi J, Mounier N, Xue X, Wang D, Ribera JM, Navarro JT, Hoffmann C, Dunleavy K, Little RF, Wilson WH, Spina M, Galicier L, Noy A, Sparano JA. Central nervous system involvement in AIDS-related lymphomas. Br J Haematol 2016, 173:857-866.

295. Wilson WH. Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. N

Engl J Med. 2016, 374:386-388.

296. Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, Jaffe ES, Wilson WH. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica 2016, 101:27-29.

297. Kreitman RJ, Stetler-Stevenson M, Jaffe ES, Conlon KC, Steinberg SM, Wilson

W, Waldmann TA, Pastan I. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity. Clin Cancer Res. 2016, 22:310-318.

298. Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero

A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2016, Epub ahead of print.

299. Nowakowski GS, Blum KA, Kahl BS, Friedberg JW, Baizer L, Little RF, Maloney

DG, Sehn LH, Williams ME, Wilson WH, Leonard JP, Smith SM. Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. J Natl Cancer Inst. 2016, 108:1-8.

300. Dunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma. Hematol Oncol

Clin North Am. 2016, 30:P1333-1343.

301. Queirós AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, Raineri E, Russiñol N, Castellano G, Beà S, Navarro A, Kulis M, Verdaguer-Dot N, Jares P, Enjuanes A, Calasanz MJ, Bergmann A, Vater I, Salaverría I, van de Werken HJ, Wilson WH, Datta A, Flicek P, Royo R, Martens J, Giné E, Lopez-

37

Guillermo A, Stunnenberg HG, Klapper W, Pott C, Heath S, Gut IG, Siebert R, Campo E, Martín-Subero JI. Cancer Cell. 2016, 30:806-821.

302. Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland, SM, Wilson, W, Dunleavy

K, Shah NN, Freeman AF. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. Front. Pediatr. 2017, 5:38.

303. Lionakis MD, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R,

Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, Gea-Banacloche J, Bhaumik S, Stetler-Stevenson M, Pittaluga S, Jaffe ES, Heiss J, Lucas N, Steinberg SM, Staudt LM, Wilson WH. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma. Cancer Cell 2017, 31:833.

304. Lai C, Roschewski M, Melani C, Pittaluga S, Shovlin M, Steinberg S, Dunleavy K,

Pack S, Jaffe ES, and Wilson WH. MYC Gene Rearrangement In Diffuse Large B-cell Lymphoma Does Not Confer a Worse Prognosis Following Dose-Adjusted-EPOCH-R. 2017. Leukemia and Lymphoma 2018, 59:505.

305. Melani,C, Major A, Schowinsky J, Roschewski M, Pittaluga S, Jaffe ES, Pack SD,

Abdullaev Z, Ahlman MA, Kwak JJ, Morgan R, Rabinovitch R, Pan Z, Haverkos BM, Gutman JA Pollyea DA, Smith CA Wilson WH (corresponding author), Kamdar M. PD-1 Blockade in Mediastinal Gray-Zone Lymphoma, N Engl J Med 2017, 377:89.

306. Navarro, A, Clot G, Martinez-Trillos A, Pinyol M, Jares P, Gonzalez-Farre B,

Martinez D, Trim N, Gernandez V, Villamor N, Colomer D, Costa D, Salaverria I, Martin0-Garcia D, Erber W, Lopez C, Jayne S, Siebert R, Dyer MJS, Wiestner A, Wilson WH, Aymerich M, Lopez-Guillermo A, Sanchez A, Campo E, Matutes E, Bea S. Improved Classification of Leukemic B-cell Lymphoproliferative Disorders Using a Transcriptional and Genetic Classifier. Haematologica 2017, 102:e360.

307. Roswarski J, Roschewski M, Lucas A, Melani C, Pittaluga S, Jaffe ES, Steinberg

SM, Waldmann TA, Wilson WH. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leuk Lymphoma 2018, 59:1466.

308. Melani C, Advani R, Roschewski M, Walters KM, Chen CC, Barrato L, Steinberg

SM, Shovlin M, Dunleavy K, Pittaluga S, Jaffe ES, Wilson WH. End-of-Treatment and serial PET imaging in Primary Mediastinal B-Cell Lymphoma following dose-adjusted EPOCH-R; a paradigm shift in clinical decision making. Haematologica 2018, 103:1337.

38

309. Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv. 2017, 1:1911.

310. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood 2018, 131:2331.

311. Melani C, Wilson WH, Roschewski M. What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R? Br J Haematol. 2019, 184:836.

312. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018, 378:1396.

313. Dunleavy K, Fanale MA, Abramson J, Noy A, Fabrizio-Caimi P, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Sterling-Lord R, Lechowicz MJ, Gaur R, Leach JW, Lucas A, Melani C, Steinberg SM, Kahl B, Friedberg JW, Roschewski M, Little RF, Bartlett NL, and Wilson WH. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol 2018. 5:609.

314. Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer

AL 3rd, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, Yang Y, Zhao H, Yu X, Xu W, Palisoc MM, Valadez RR, Davies-Hill T, Wilson WH, Chan WC, Jaffe ES, Gascoyne RD, Campo E, Rosenwald A, Ott G, Delabie J, Rimsza LM, Rodriguez FJ, Estephan F, Holdhoff M, Kruhlak MJ, Hewitt SM, Thomas CJ, Pittaluga S, Oellerich T, Staudt LM. A multiprotein supercomplex controlling oncogenic signaling in lymphoma. Nature 2018, 560:387.

315. Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE,

le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

39

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018. 32:1768.

316. Melani C, Roschewski M, Wilson WH. End-of-treatment and serial PET imaging

has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al. Haematologica 2018.103:382.

317. Wright GW, Wilson WH, Staudt LM. Genetics of Diffuse Large B-Cell Lymphoma.

N Engl J Med 2018. 379:493.

318. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Levy R, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas RO, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol 2018. 36:2845.

319. Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE,

Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ. ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica 2019. 104:65.

320. Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen

H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 2019. 133:1313.

321. Roswarski J, Roschewski M, Melani C, Pittaluga S, Lucas A, Steinberg SM, Jaffe

ES, Waldmann TA, Wilson WH. Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas. Leuk Lymphoma 2019. 60:2062.

322. Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MS, Chabon JJ, Stehr

H, Liu CL, Tibshirani R, Maeda LS, Gupta NK, Khodadoust MS, Advani RH, Newman AM, Dührsen U, Hüttmann A, Meignan M, Casasnovas O, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. Reply to J. Wang et al. J Clin Oncol 2019. 37:755.

40

323. Ben-Yakov G, Alao H, Haydek JP, Fryzek N, Cho MH, Hemmati M, Samala V, Shovlin M, Dunleavy K, Wilson W, Jones EC, Rotman Y. Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. Hepatol Commun 2018. 3:220.

324. Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Gonçalves PH,

Ramaswami R, Marshall VA, Miley W, Steinberg SM, Little RF, Wilson W, Filie AC, Pittaluga S, Jaffe ES, Whitby D, Yarchoan R, Uldrick TS. Viral, immunologic, and clinical features of primary effusion lymphoma. Blood 2019. 133:1753.

325. Wilson WH. Dose-adjusted EPOCH-R therapy in MYC-rearranged diffuse large B-

cell lymphoma: not yet the standard of care - Authors' reply. Lancet Haematol 2019. 6:120.

326. Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D,

Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J Clin Oncol 2019. 37:1285.

327. Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC,

Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol 2019. 37:1790.

328. Melani C, Wilson WH, Roschewski M. Liquid biopsy in non-Hodgkin's lymphoma.

Hematol Oncol 2019. 37:70.

329. Miljkovic MD, Roschewski M, Dunleavy K, Wilson WH. Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma. Leuk Lymphoma 2019. https://doi.org/10.1080/10428194.2019.1627540.

330. Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen

U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell 2019. 178:699.

41

331. Young RM, Phelan JD, Wilson WH, Staudt LM. Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. Immunol Rev 2019. 291:190.

332. Howe MK, Dowdell K, Roy A, Niemela JE, Wilson W, McElwee JJ, Hughes JD,

Cohen JI. Magnesium Restores Activity to Peripheral Blood Cells in a Patient With Functionally Impaired Interleukin-2-Inducible T Cell Kinase. Front Imunol 2019. https://doi.org/10.3389/fimmu.2019.02000

Bibliography Statistics: Google Scholar Citations All: 50894. Since 2014: 21284 h-index All: 93. Since 2014: 64